SUBSCRIBE: Print / eNewsletter
In this article, we review the findings of the IDEA study and discuss the optimal duration of oxaliplatin-based adjuvant chemotherapy using patient-based risk factors.
This article reviews the critical issues of quality control and standardization of PHY906 and other herbal medicines, and highlights the importance of high-quality material for the conduct of preclinical and clinical studies, for cancer patients.
The issue of tumor heterogeneity is real, and it is present on several different levels. Without question, the presence of tumor heterogeneity has important clinical implications, and at this time, it represents a significant challenge to the success of cancer therapy.
It was originally hoped that the presence of mutations in KRAS and other related genes would provide an easy answer as to whether to administer anti-EGFR antibody therapy to a given metastatic colorectal cancer patient. However, in nature nothing is simple, and there are a number of issues that practicing clinicians should be made aware of.
Over the past few years, significant efforts have focused on developing and validating molecular biomarkers to better define the subset of patients with stage II disease who might derive benefit from adjuvant therapy.
This article reviews the main issues that must be considered in metastatic colorectal cancer from the surgical oncology and medical oncology perspectives, respectively.
In this issue of ONCOLOGY, Golan and Javle present a timely review of the current status of the insulin growth factor-1 receptor (IGF-1R) signaling pathway as a therapeutic target, with a specific focus on gastrointestinal (GI) cancers.
Anti-EGFR (epidermal growth factor receptor) therapies, including tyrosine kinase inhibitors (TKIs) and monoclonal antibodies, demonstrate activity in a variety of tumor types. While both inhibit the EGFR pathway, they act via different mechanisms.
Colorectal cancer is a worldwide public health problem, with nearly 800,000
new cases diagnosed each year resulting in approximately 500,000
deaths. In the United States, it is the second leading cause of cancer mortality,
and nearly 60,000 deaths will be attributed to this disease in 2005. When
diagnosed as advanced, metastatic disease, colorectal cancer is traditionally associated
with a poor prognosis, with 5-year survival rates in the range of 5% to 8%. This
survival rate has remained unchanged over the past 35 to 40 years. However, during
the past 5 years, significant advances have been made in treatment options so that
improvements in 2-year survival are now being reported, with median survival rates
in the 21- to 24-month range in patients with metastatic disease.
Colorectal cancer is a worldwide public health problem, with nearly 800,000
new cases diagnosed each year resulting in approximately 500,000
deaths. In the United States, it is the second leading cause of cancer mortality,
and nearly 60,000 deaths will be attributed to this disease in 2005. When
diagnosed as advanced, metastatic disease, colorectal cancer is traditionally associated
with a poor prognosis, with 5-year survival rates in the range of 5% to 8%. This
survival rate has remained unchanged over the past 35 to 40 years. However, during
the past 5 years, significant advances have been made in treatment options so that
improvements in 2-year survival are now being reported, with median survival rates
in the 21- to 24-month range in patients with metastatic disease.
We've noticed that you're using an ad blocker
Our content is brought to you free of charge because of the support of our advertisers. To continue enjoying our content, please turn off your ad blocker.
